Every 8-K that Harrow Health (HROWL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HROWL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HROWL filings page.
Harrow, Inc. furnished a corporate presentation as an exhibit to a current report. The presentation, dated June 2026, may be used by management at investor conferences and meetings with analysts and other interested parties. The material is provided under Regulation FD as supplemental information.
The company states that the presentation and related disclosure are furnished rather than filed, which means they are not subject to certain liability provisions and are not automatically incorporated into other securities filings unless specifically referenced.
Harrow, Inc. reported first-quarter 2026 revenue of $44.2 million, down 8% from $47.8 million a year earlier, mainly due to VEVYE gross-to-net adjustments and softer compounded product sales. Gross margin declined to 61% from 68%, and the company posted a net loss of $27.6 million, wider than the prior-year loss of $17.8 million. Adjusted EBITDA was a loss of $12.7 million versus a $2.0 million loss last year, reflecting heavier commercial and R&D investment.
Despite weaker reported earnings, demand for key brands remained strong. VEVYE generated $20.9 million in revenue after an estimated $8 million non-recurring gross-to-net reduction and achieved about 14% branded dry eye market share, surpassing XIIDRA on monthly total prescriptions. IHEEZO unit demand rose 18% year over year, and TRIESENCE demand more than doubled, marking a sixth straight growth quarter.
Harrow ended the quarter with $94.6 million in cash and reiterated its full-year 2026 guidance for revenue of $350–$365 million and Adjusted EBITDA of $80–$100 million, with performance weighted to the second half. Second-quarter 2026 revenue is expected between $71 million and $81 million, supported by an expanded sales force, growing prescription trends for VEVYE, and increasing adoption of IHEEZO and TRIESENCE.
Harrow, Inc. has priced a private offering of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030. The new notes will be issued as additional notes under the same indenture as the existing $250,000,000 8.625% notes, forming a single series with identical terms apart from issuance date and issue price.
The notes, guaranteed by certain current and future restricted subsidiaries, are expected to close on March 27, 2026, bear interest at 8.625% and mature on September 15, 2030, with semi-annual cash interest payments on March 15 and September 15. Harrow plans to use the net proceeds for general corporate purposes, including potential growth initiatives, product development and strategic business opportunities. The offering is being made only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S.
Harrow, Inc. filed a current report to furnish an updated corporate investor presentation under Regulation FD. The presentation, dated March 2026, is provided as Exhibit 99.1 and may be used by management in investor conferences and meetings.
The company specifies that this material is being furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is only incorporated into other securities filings if expressly referenced.
Harrow, Inc. reported strong growth for Q4 and full-year 2025 and issued 2026 guidance. Quarterly revenue reached $89.1 million, up 33% from $66.8 million, while full-year revenue rose 36% to $272.3 million from $199.6 million. Q4 GAAP net income was $6.6 million, though the company posted a $5.1 million net loss for 2025. Adjusted EBITDA grew to $24.2 million in Q4 and $61.9 million for the year. Operating cash flow swung to a positive $43.9 million in 2025 from $(22.2) million in 2024, and cash and cash equivalents were $72.9 million at year-end. Management highlighted strong momentum in key ophthalmic brands VEVYE, IHEEZO and TRIESENCE and outlined plans to expand sales teams and invest in growth initiatives. For 2026, Harrow guides to $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA, with results expected to be more heavily weighted to the second half of the year.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.